drugset / Trial / NCT03133793
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Phase 2
Completed
216 enrolled
University of Kansas Medical Center
National Institute on Aging (NIA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
Timeline
- Start
- 2018-02-05
- Primary completion
- 2021-03-12
- Completion
- 2021-03-12
Publications
- Pierce JD, Shen Q, Mahoney DE, Rahman F, Krueger KJ, Diaz FJ, Clark L, Smith C, Vacek J, Hiebert JB. Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2022 Aug 1;176:79-88. doi: 10.1016/j.amjcard.2022.04.031. Epub 2022 May 27.
- Pierce JD, Mahoney DE, Hiebert JB, Thimmesch AR, Diaz FJ, Smith C, Shen Q, Mudaranthakam DP, Clancy RL. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. BMC Cardiovasc Disord. 2018 Apr 2;18(1):57. doi: 10.1186/s12872-018-0796-2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RIBOSE (PYRANOSE) | Small molecule | 15 g | Oral |
| Subject | Ubiquinol | Unknown | 300 mg | Oral |